Andrea Imbrogno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andrea Imbrogno has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Dario Fabbri
Pancreas Unit, Department of Digestive Diseases and Internal Medicine, Sant’Orsola-Malpighi Hospital, Bologna
8 shared publications - Raffaele Pezzilli
Department of Gastroenterology, San Carlo Hospital, Potenza
7 shared publications - Roberto Corinaldesi
Department of Clinical Medicine, Digestive Diseases and Internal Medicine, University of Bologna, St. Orsola-Malpighi Hospital, Bldg #5, Nuove Patologie, Via Massarenti 9, 40138, Bologna, Italy
4 shared publications - Alessandra Barassi
Department of Health Sciences, Università degli Studi of Milan, 20142 Milan, Italy
2 shared publications Antonina Pigna
1 shared publicationAntonio M. Morselli-Labate
1 shared publication
Latest Publications
- 1 November 2012
- Published by Elsevier in Digestive and Liver Disease
- Vol. 44 (11) , 965-966
Acute recurrent pancreatitis and pancreas divisum: Appearances can be deceiving
- 1 November 2012
- Published by Elsevier in Digestive and Liver Disease
- Vol. 44 (11) , 965-966
Acute recurrent pancreatitis and pancreas divisum: Appearances can be deceiving
- 9 September 2011
- Vol. 12 (5) , 495-6
Early treatment of acute pancreatitis: do not forget the need for water.
- 9 September 2011
- Vol. 12 (5) , 495-6
Early treatment of acute pancreatitis: do not forget the need for water.
- Open Access
- 29 June 2011
- Published by PAGEPress Publications in Emergency Care Journal
- Vol. 7 (2) , 5
Acute Pancreatitis: Pathophysiology, Clinical Aspects, Diagnosis e Treatment
Acute pancreatitis is an acute inflammation of the pancreas. The clinical classification of the disease recognizes the mild acute pancreatitis, characterized by the absence of local and/or systemic complications, and the severe disease, characterized by the presence of local complications such as necrosis, abscess or pseudocysts and/ or distant organ failure. Gallstones constitute the predominant etiological factor. The severity assessment is essential for proper initial treatment of the disease. Primary objectives to achieve in the treatment of acute pancreatitis essentially are: pain control, electrolyte support and energy intake, removal of the causal agent, attenuation of the inflammation, and prevention and eventual treatment of local and systemic complications of necrotizing forms.
- 29 June 2011
- Published by PAGEPress Publications in Emergency Care Journal
- Vol. 7 (2) , 5
Open AccessAcute Pancreatitis: Pathophysiology, Clinical Aspects, Diagnosis e Treatment
Acute pancreatitis is an acute inflammation of the pancreas. The clinical classification of the disease recognizes the mild acute pancreatitis, characterized by the absence of local and/or systemic complications, and the severe disease, characterized by the presence of local complications such as necrosis, abscess or pseudocysts and/ or distant organ failure. Gallstones constitute the predominant etiological factor. The severity assessment is essential for proper initial treatment of the disease. Primary objectives to achieve in the treatment of acute pancreatitis essentially are: pain control, electrolyte support and energy intake, removal of the causal agent, attenuation of the inflammation, and prevention and eventual treatment of local and systemic complications of necrotizing forms.
- 6 May 2011
- Vol. 12 (3) , 309-10
The effect of pathological types of intraductal papillary mucinous neoplasms of the pancreas on survival.
- 6 May 2011
- Vol. 12 (3) , 309-10
The effect of pathological types of intraductal papillary mucinous neoplasms of the pancreas on survival.
- 1 April 2011
- Published by Elsevier in Hepatobiliary & Pancreatic Diseases International
- Vol. 10 (2) , 191-195
Is the pancreas affected in patients with septic shock? — a prospective study
- 1 April 2011
- Published by Elsevier in Hepatobiliary & Pancreatic Diseases International
- Vol. 10 (2) , 191-195
Is the pancreas affected in patients with septic shock? — a prospective study
- 17 March 2011
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 49 (6) , 1047-1051
Plasma concentrations of angiogenetic factors and angiogenetic inhibitors in patients with ductal pancreatic neoplasms. A pilot study
Background: The aim of the study was to evaluate the circulating concentrations of vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor-2 (VEGFR-2), vascular endothelial growth factor-D (VEGF-D) and endostatin in patients with intraductal papillary mucinous neoplasm (IPMN), and in those with ductal adenocarcinomas. Methods: Sixty patients (32 males, 28 females, mean age 69.3±11.3 years) were enrolled: 31 (51.7%) had IPMNs and 29 (48.3%) had histologically confirmed pancreatic adenocarcinomas. Thirty blood donors were also studied as controls. In all study subjects, the concentrations of VEGF, VEGF-D, VEGFR-2, and endostatin were determined using enzyme-linked immunosorbent assays. Results: Serum concentrations of VEGF, VEGF-D, and VEGFR-2 were significantly higher in patients with pancreatic ductal adenocarcinoma and those with IPMNs compared with healthy subjects, while endostatin was significantly higher only in patients with pancreatic ductal adenocarcinoma compared with healthy subjects. Within the group of patients, VEGFR-2 was significantly higher in patients with ductal adenocarcinoma compared to those with IPMNs. The sensitivity and the specificity of VEGFR-2 in differentiating patients with ductal adenocarcinomas from those with IPMN at a cut-off range of 4003–4034 pg/mL was 86.2% and 54.8%, respectively. Conclusions: IPMNs have serum VEGFR-2 concentra-tions different from those in patients with ductal adenocarcinomas. However, serum VEGFR-2 cannot be routinely utilized to differentiate IPMNs from pancreatic ductal adenocarcinomas.
- 17 March 2011
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 49 (6) , 1047-1051
Plasma concentrations of angiogenetic factors and angiogenetic inhibitors in patients with ductal pancreatic neoplasms. A pilot study
Background: The aim of the study was to evaluate the circulating concentrations of vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor-2 (VEGFR-2), vascular endothelial growth factor-D (VEGF-D) and endostatin in patients with intraductal papillary mucinous neoplasm (IPMN), and in those with ductal adenocarcinomas. Methods: Sixty patients (32 males, 28 females, mean age 69.3±11.3 years) were enrolled: 31 (51.7%) had IPMNs and 29 (48.3%) had histologically confirmed pancreatic adenocarcinomas. Thirty blood donors were also studied as controls. In all study subjects, the concentrations of VEGF, VEGF-D, VEGFR-2, and endostatin were determined using enzyme-linked immunosorbent assays. Results: Serum concentrations of VEGF, VEGF-D, and VEGFR-2 were significantly higher in patients with pancreatic ductal adenocarcinoma and those with IPMNs compared with healthy subjects, while endostatin was significantly higher only in patients with pancreatic ductal adenocarcinoma compared with healthy subjects. Within the group of patients, VEGFR-2 was significantly higher in patients with ductal adenocarcinoma compared to those with IPMNs. The sensitivity and the specificity of VEGFR-2 in differentiating patients with ductal adenocarcinomas from those with IPMN at a cut-off range of 4003–4034 pg/mL was 86.2% and 54.8%, respectively. Conclusions: IPMNs have serum VEGFR-2 concentra-tions different from those in patients with ductal adenocarcinomas. However, serum VEGFR-2 cannot be routinely utilized to differentiate IPMNs from pancreatic ductal adenocarcinomas.
- 9 March 2011
- Vol. 12 (2) , 209-10
Lymphocytes and pancreatic cancer: the effects of these cells on diagnosis and patient survival.
- 9 March 2011
- Vol. 12 (2) , 209-10
Lymphocytes and pancreatic cancer: the effects of these cells on diagnosis and patient survival.
- Open Access
Does Ablation Technique Utilized in the Management of Unresectable Locally Advanced Pancreatic Adenocarcinoma?
Radiofrequency ablation in the management of advanced pancreatic cancer should be no longer utilized in patients with locally advanced or metastatic pancreatic adenocarcinoma.
Open AccessDoes Ablation Technique Utilized in the Management of Unresectable Locally Advanced Pancreatic Adenocarcinoma?
Radiofrequency ablation in the management of advanced pancreatic cancer should be no longer utilized in patients with locally advanced or metastatic pancreatic adenocarcinoma.